Boehringer Ingelheim launches RenuTend™: a new stem cell therapy to improve the healing of tendon and suspensory ligament injuries in horses
It takes years of diligent training as well as a trusting relationship between horse and rider to reach their full potential as a team. That’s why a tendon or ligament injury can be devastating for horse owners, riders and trainers. For equine athletes, the diagnosis may mean many months of treatment and rehabilitation with an unknown outcome, and potential for long term impact on their ability to perform.
Boehringer Ingelheim has now received approval in Europe for RenuTend™, the first product licensed to improve healing of tendon and suspensory ligament injuries in horses. RenuTend™ is administered by intralesional injection and complements Boehringer Ingelheim’s other equine stem cell product Arti-Cell® FORTE, which is authorised to treat mild to moderate recurrent lameness associated with non-septic joint inflammation in horses.
“We are delighted to add RenuTend™ to our portfolio of stem cell products for horses, offering veterinarians a new therapeutic option for treating tendon and suspensory ligament injuries. This product demonstrates the company's commitment to bringing innovation to improve the lives of horses and the people who love them,” comments Liz Barrett, Head of Global Strategic Marketing, Equine at Boehringer Ingelheim. “RenuTend™ will allow more riders, owners and trainers to reimagine the dreams a tendon injury jeopardizes, by optimizing the possibilities for their horse to return to work with reduced potential for reinjury.”
Tendon and ligament lesions don’t always heal properly, as scar tissue can be less elastic than healthy tissue, and reinjury rates can be up to 80 percent. This can mean the end of a career for many horses. RenuTend™ is a targeted stem cell treatment with proven efficacy and repeatable results. It improves the quality of tendon healing by promoting parallel alignment of the right type of fibres and decreases the amount of scar tissue formed.
RenuTend™ will be available across the European Union. The approval for Great Britain is still pending.
Please click on the link for ‘Notes to Editors’ and ‘References’:
https://www.boehringer-ingelheim.com/animal-health/companion-animals/horses/stem-cell-therapy-tendon-and-ligament-injuries-horses
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220421005467/en/
Contact information
Boehringer Ingelheim Animal Health Communication
Marisa Lehn
552 16 Ingelheim, Germany
Phone: +49 6132 77 171241
Email: press@boehringer-ingelheim.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Antognolla at International Hospitality Investment Forum: Growing Interest in the Italian Market from Hotel Operators and Investors25.4.2024 17:39:00 EEST | Press release
Antognolla Resort & Residences joined world-class hospitality experts at the Hospitality Investment Forum EMEA (IHIF EMEA) on 15-17 April in Berlin. With over 2,500 attendees this year, IHIF EMEA remains one of the largest gatherings of industry professionals in the region. Hospitality experts and event participants reaffirmed the growing interest among hotel operators in Italy, evident from the number of prestigious international brands entering the Italian market. The hospitality market in the country is becoming more identity-driven, with the majority of hotel keys in the upscale and luxury category being branded. International operators are increasingly attracted to the country year by year: almost 70% of the properties in the pipeline will belong to international chains by 2026. Andrey Yakunin, Chairman of the Board of Directors of Antognolla Resort & Residences commented: “As international experts discussed during IHIF, identity-driven, branded projects are set to become the lead
Digital Transformation’s Next Era: Generative AI and Laserfiche 12 at 2024 Empower Conference25.4.2024 17:30:00 EEST | Press release
Preparing organizations for the next AI-driven phase of digital transformation is on the agenda at the 2024 Empower conference, hosted by Laserfiche — the leading SaaS provider of intelligent content management and business process automation — in Las Vegas through April 25. Laserfiche shines a spotlight on solutions that reduce complexity and accelerate information flow across the enterprise to help organizations manage increasing amounts of data. Empower attendees got an early look at the latest Laserfiche AI features, including Laserfiche AI Document Summarization. The new offering, powered by generative AI, eliminates tedious sifting through documents by generating concise summaries of documents containing either text or transcribed audio. Laserfiche AI Document Summarization, which represents one milestone in the Laserfiche AI vision to transform the workplace, will be available in the upcoming Laserfiche Cloud release on April 30, 2024. “At Laserfiche, we believe AI will impact p
Alpha Blue Ocean Group and Europlasma, Expert in Depollution Solutions, Announce the Signing of a New €30 Million Financing Agreement25.4.2024 17:00:00 EEST | Press release
Environmental Performance Financing (EPF), a subsidiary of the Alpha Blue Ocean group, is proud to announce its collaboration with Europlasma (ALEUP:FP), a leader in depollution, material recovery, and decarbonation solutions, for the establishment of a bond financing arrangement. This financing aims to support the Group's growth and development, particularly in key initiatives such as: The acquisition of MG-Valdunes: Europlasma has obtained the green light for the acquisition of MG-Valdunes' business assets, a crucial step towards strengthening industrial sovereignty and relaunching Valdunes' historic activities. The development of the Forges de Tarbes: Funds will also be allocated to increasing the production capacities of the Forges de Tarbes, which are facing growing demand, particularly in the defense sector. The continued development of historical activities: A significant portion of the funds will be dedicated to the ongoing development of depollution, decarbonation, and hazardo
Interactive Brokers Announces Extended Trading Hours for US Treasury Bonds25.4.2024 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, today announced a significant expansion of trading hours for US Treasury bonds on its platform. Clients around the world can now trade US Treasury bonds for 22 hours each day. The trading session closes daily at 5:00 pm Eastern Time (ET), reopens at 8:00 pm Eastern Daylight Time (EDT) and continues until 5:00 pm the following day. During Eastern Standard Time (EST), the market operates from 7:00 pm to 5:00 pm. This is a significant extension from the previous nine hours per day. This groundbreaking expansion caters especially to Interactive Brokers' global clients, allowing them to trade US Treasuries during their local trading hours. In addition, all clients are now able to respond swiftly to global market news and economic events as they occur, regardless of time or location. "The extension of trading hours for US Treasury bonds represents a significant enhancement to our offerings," said Thomas Frank, Executi
Cannatrol, Creators of Breakthrough Postharvest Cannabis Technology, Receive Two European Patent Approvals25.4.2024 15:03:00 EEST | Press release
Cannatrol, the creators of the only total dry, cure and store system for the cannabis industry, announced today the approval of two European patents for its Vaportrol® Technology, protecting the proprietary technology throughout the European Union. “As the European cannabis industry grows, demand for precision drying, curing and storage technologies continues to expand,” said David Sandelman, co-founder, COO and CTO of Cannatrol. “Cannatrol’s proven environmental-control system ensures top-quality cannabis through a repeatable, consistent process, and it’s appropriate for any scale of cultivation, from large-scale greenhouse production to home growers.” Cannatrol’s patented postharvest technology is proven to increase yields and curing efficiency, and delivers on average 16% higher terpene retention when compared to traditional drying and curing methods, according to independent testing by The Cannabis Research Coalition. Throughout drying, curing and storage, the environment will stay
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom